vimarsana.com

குளியல் அங்கயலோசிங் ஸ்பான்டைலிடிஸ் செயல்பாட்டு குறியீட்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health Impairment in Spondyloarthritis Associated With High Disease Activity, Worsening Functionality, and Concomitant Fibromyalgia

Health Impairment in Spondyloarthritis Associated With High Disease Activity, Worsening Functionality, and Concomitant Fibromyalgia
rheumatologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rheumatologyadvisor.com Daily Mail and Mail on Sunday newspapers.

European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis

European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6] - Approvals underscore AbbVie s longstanding commitment to deliver innovative medicines for people living with rheumatic diseases

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.